Update on treatment options for Lambert–Eaton myasthenic syndrome: focus on use of amifampridine
Open Access
- 1 May 2011
- journal article
- review article
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. 7 (1) , 341-349
Abstract
In Lambert–Eaton myasthenic syndrome (LEMS), antibodies against presynaptic voltage-gated calcium channels reduce the quantal release of acetylcholine, causing muscle weakness and autonomic dysfunction. More than half of the affected patients have associated small cell lung cancer, and thorough screening for an underlying malignancy is crucial. The mainstay of treatment for LEMS is symptomatic but immunotherapy is needed in more severely affected patients. Symptomatic therapies aim at increasing the concentration of acetylcholine at the muscle endplate. While acetylcholinesterase inhibitors were the first drugs to be used for the amelioration of symptoms, 3,4-diaminopyridine (3,4-DAP, amifampridine) has been shown to be more effective. 3,4-DAP blocks presynaptic potassium channels, thereby prolonging the action potential and increasing presynaptic calcium concentrations. This then results in increased quantal release of acetylcholine. The efficacy of 3,4-DAP for increasing muscle strength and resting compound muscle action potentials has been demonstrated by four placebo-controlled trials. Side effects are usually mild, and the most frequently reported are paresthesias. The most common serious adverse events are epileptic seizures. 3,4-DAP is currently the treatment of choice in patients with Lambert–Eaton myasthenic syndrome.Keywords
This publication has 42 references indexed in Scilit:
- Treatment for Lambert-Eaton myasthenic syndromeCochrane Database of Systematic Reviews, 2011
- Autoimmune mediated neuromuscular junction defectsCurrent Opinion in Neurology, 2010
- Screening for tumours in paraneoplastic syndromes: report of an EFNS Task ForceEuropean Journal of Neurology, 2010
- Guidelines for treatment of autoimmune neuromuscular transmission disordersEuropean Journal of Neurology, 2010
- Current therapy for Lambert–Eaton myasthenic syndrome: development of 3,4-diaminopyridine phosphate salt as first-line symptomatic treatmentCurrent Medical Research and Opinion, 2010
- 3,4‐Diaminopyridine is more effective than placebo in a randomized, double‐blind, cross‐over drug study in LEMSMuscle & Nerve, 2009
- Available treatment options for the management of Lambert-Eaton myasthenic syndromeExpert Opinion on Pharmacotherapy, 2006
- Cardiac Arrest Following an Iatrogenic 3, 4-Diaminopyridine Intoxication in a Patient with Lambert-Eaton Myasthenic SyndromeJournal of Toxicology: Clinical Toxicology, 1995
- 3,4-Diaminopyridine in the Treatment of Lambert–Eaton Myasthenic SyndromeNew England Journal of Medicine, 1989
- Novel drug of choice in Eaton-Lambert syndrome.Journal of Neurology, Neurosurgery & Psychiatry, 1983